Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $121,230.00 in Stock

Key Points

• Insider sale: Kymera insider Noah Goodman sold 1,347 shares on April 14 at $90 for $121,230, cutting his stake to 50,195 shares (a 2.61% decrease); he also sold 10,264 shares on April 9–10 for roughly $897,800 earlier in the month.
• Earnings miss: Kymera reported Q results with EPS of -$0.97 vs. consensus -$0.77 and revenue of $2.87M vs. $14.8M expected, with revenue down 60.8% year-over-year.
• Analyst sentiment: Despite the weak quarter, analysts remain largely bullish with a MarketBeat consensus of "Moderate Buy" and an average target price of $118.90, and multiple firms issuing Buy/Overweight ratings.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Noah Goodman sold 1,347 shares of the stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $90.00, for a total transaction of $121,230.00. Following the completion of the transaction, the insider owned 50,195 shares in the company, valued at $4,517,550. This represents a 2.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Noah Goodman also recently made the following trade(s):

• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total transaction of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.50, for a total transaction of $723,100.00.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR traded down $2.86 during mid-day trading on Thursday, reaching $86.14. The stock had a trading volume of 554,950 shares, compared to its average volume of 732,626. The business has a 50 day simple moving average of $83.69 and a 200 day simple moving average of $74.15. The firm has a market capitalization of $7.03 billion, a price-to-earnings ratio of -23.41 and a beta of 2.28. Kymera Therapeutics, Inc. has a twelve month low of $24.72 and a twelve month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to analysts' expectations of $14.80 million. During the same quarter in the previous year, the firm posted ($0.88) earnings per share. The firm's revenue for the quarter was down 60.8% compared to the same quarter last year. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Morgan Stanley reiterated an "overweight" rating and issued a $123.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. BTIG Research decreased their target price on shares of Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating for the company in a research note on Thursday, February 26th. UBS Group upped their target price on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a "buy" rating in a research note on Tuesday, March 3rd. Citigroup upped their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a "buy" rating in a research note on Monday, March 2nd. Finally, Piper Sandler upped their target price on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $118.90.

Hedge Funds Weigh In On Kymera Therapeutics

Large investors have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its stake in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock worth $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC lifted its stake in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. raised its stake in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after acquiring an additional 1,083 shares during the period. Bessemer Group Inc. raised its stake in Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company's stock worth $53,000 after acquiring an additional 815 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Kymera Therapeutics during the fourth quarter worth about $63,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.